Bladder p75^NTR-Mediated Anti-Inflammatory Response via the TLR4/TRAF6/NF-κB Axis.

Area of Science:

• Urology
• Immunology
• Cell Biology

Background:

• Recurrent bacterial cystitis can lead to interstitial cystitis/bladder pain syndrome (IC/BPS).
• Toll-like receptor 4 (TLR4) activation by lipopolysaccharide (LPS) upregulates pro-inflammatory p75^NTR signaling.
• p75^NTR is implicated in inflammatory responses within bladder cells.

Purpose of the Study:

• To evaluate the efficacy of p75^NTR antagonist THX-B in modulating LPS-induced inflammation in bladder cells.
• To investigate the role of p75^NTR in inflammatory signaling pathways in urothelial (URO) and smooth muscle (SMC) cells.
• To assess the therapeutic potential of p75^NTR inhibition for cystitis-related bladder symptoms.

Main Methods:

• In vitro assessment of p75^NTR expression and LPS activation in URO and SMC cells.
• Treatment with p75^NTR antagonist THX-B to observe effects on inflammatory markers (TNF-α, ERK, p38MAPK, JNK, NF-κB, iNOS, NO).
• In vivo study involving intraurethral LPS instillation and intraperitoneal THX-B administration to assess bladder inflammation and tissue function.

Main Results:

• In URO cells, p75^NTR antagonism reduced TNF-α but did not affect ERK, p38MAPK, iNOS, or NO levels.
• In SMC cells, THX-B prevented LPS-induced JNK phosphorylation, NF-κB translocation, and TRAF6 association with p75^NTR.
• LPS instillation increased bladder inflammation and JNK activation, which THX-B partially mitigated, but did not affect muscle contraction.

Conclusions:

• p75^NTR plays a differential role in LPS-induced inflammation in urothelial and smooth muscle bladder cells.
• p75^NTR antagonism demonstrates potential in ameliorating specific inflammatory aspects of cystitis.
• Targeting p75^NTR may offer a therapeutic strategy for reducing bladder symptoms associated with cystitis.